top of page
Targeting the biology behind hard-to-treat disease
When cells sense danger, they mount a coordinated defense. When that response stays switched on, it becomes a driver of some of medicine's most stubborn chronic conditions. SynapCrest exists to change that. We are advancing a new therapeutic designed to calm the overactive cell-danger response and restore healthy cellular balance — with the goal of giving patients relief that today's options cannot reach.
A target at the root of chronic illness
SynapCrest is built around a single, high-conviction driver of chronic disease. By acting on the biology that keeps the cell-danger response switched on, our future therapeutic aims to reach conditions that today have few real options.
A rigorous path to the clinic
Every candidate advances only after clearing a demanding bar of evidence. We hold our future therapeutic to the standard patients deserve: safety, precision, and the potential to make a real difference.
Six candidates in preclinical validation
Six distinct therapeutic candidates are now moving through preclinical validation — each a step toward a treatment designed to change what chronic illness looks like for patients.
Where we're headed
Our lead program is moving toward its first therapeutic — one built to reset the cell-danger response and give people living with chronic illness a genuine path forward. This is the future we are building.
Where the biology is hardest, we go to work
bottom of page